Post by PharmaBoardroom

EU rules designed for struggling manufacturers can cut off public support to pre-revenue biotechs The problem? In biotech, spending years in the red before generating revenue isn't a sign of failure but just how drug development works. This is one of the structural barriers Viola Bronsema, CEO of BIO Deutschland e. V., is pushing to fix as Germany bids to become a globally recognised biotech hub. BIO Deutschland represents over 380 members spanning everything from cell and gene therapy to novel food and industrial biotechnology, and Bronsema argues the sector is now too strategically important to be held back by frameworks built for a different era. In conversation with PharmaBoardroom's Roxane Höck, she covers: - why Germany's coalition agreement marks a turning point for biotech - what the BioNTech SE/Pfizer story reveals about Europe's scale-up problem - and why the real lesson of mRNA vaccines is about ecosystems, not individual companies Read more at: https://lnkd.in/e2s63BJM